Organon (OGN) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

Business performance and strategic highlights

• Achieved strong 2024 performance, with NEXPLANON growing 15% and expected to surpass $1 billion in 2025.

• Completed major business development deals, including Emgality and Dermavant acquisitions, expanding into dermatology and emerging markets.

• VTAMA's atopic dermatitis indication offers a robust opportunity, with a unique label and strong early prescription trends.

• 2025 focus is on offsetting Atozet's $200M+ LOE headwind, with new product growth and biosimilar launches planned.

• Restructuring and OpEx efficiency initiatives aim to maintain a 31% EBITDA margin floor despite product transitions.

Product and pipeline developments

• VTAMA expected to generate $150M revenue in 2024, with a target of $500M within 3-5 years; OpEx leverage anticipated as sales ramp.

• NEXPLANON's five-year indication launches in Q4 2025, with robust efficacy data and new patient segments targeted.

• Forendo's endometriosis asset to report phase 2a/2b data by July, with potential phase III initiation in 2025 and launch around 2029.

• Denosumab biosimilar launches in Q4 2025, with pertuzumab biosimilar following in 2026/2027; aim for annual or biennial biosimilar launches.

• Fertility segment rebounding in 2025, with high single- to low double-digit growth expected.

Financial outlook and capital allocation

• FX headwinds expected to impact 2025 revenue by ~$200M, with about half flowing through to EBITDA.

• Free cash flow for 2024 and 2025 targeted at ~$1B, with leverage expected to fall below 4x by end of 2025.

• Manufacturing separation from Merck to add 2-3 margin points by 2027-2029, supporting future operating leverage.

• Capital allocation remains disciplined, balancing accretive deals like Emgality with high-margin growth assets like VTAMA.

• Near-term focus on maintaining leverage below 4x, with flexibility for strategic deals.